Supernus Pharmaceuticals, Inc. (SUPN) Q1 2013 Earnings Results

Supernus Pharmaceuticals Misses on Revenue, Stock Up 4.49%

Supernus Pharmaceuticals reported a loss per share of $-0.60, which was slightly better than expected. However, there was no revenue reported, leading to uncertainty about the company's performance. The stock reacted positively, increasing by 4.49%, possibly due to the smaller-than-expected loss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+4.76%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Supernus Pharmaceuticals Misses on Revenue, Stock Up 4.49%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Misses on Revenue, Stock Up 4.49%

Key numbers

Management commentary